TTM Technologies R&D increased by 13.5% to $7.81M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 3.2%, from $8.06M to $7.81M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 12.4% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.18M | $4.42M | $5.07M | $5.56M | $5.23M | $7.32M | $6.70M | $7.09M | $6.42M | $6.17M | $7.59M | $7.32M | $8.55M | $8.05M | $7.92M | $8.06M | $7.01M | $7.04M | $6.88M | $7.81M |
| QoQ Change | — | +5.8% | +14.7% | +9.5% | -5.8% | +39.9% | -8.5% | +5.8% | -9.3% | -3.9% | +23.0% | -3.5% | +16.7% | -5.8% | -1.6% | +1.8% | -13.1% | +0.4% | -2.2% | +13.5% |
| YoY Change | — | — | — | — | +25.1% | +65.5% | +32.1% | +27.5% | +22.8% | -15.7% | +13.3% | +3.3% | +33.0% | +30.5% | +4.4% | +10.1% | -18.0% | -12.6% | -13.2% | -3.2% |